Lucidin from Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins.

Breast cancer remains a significant global health concern, with approximately 2.3 million diagnosed cases and 670,000 deaths annually. Current targeted therapies face challenges such as resistance and adverse side effects.

Dysmenorrhea Among Women Living in Saudi Arabia: Prevalence, Determinants, and Impact.

Dysmenorrhea, or painful menstruation, is one of the most prevalent conditions among adolescents and young females globally, significantly affecting academic performance, quality of life, and social interactions. Despite its high prevalence, dysmenorrhea has been rarely investigated in Saudi Arabia, resulting in a scarcity of national data. This study aimed to evaluate the prevalence, severity, and determinants of dysmenorrhea among females in Saudi Arabia.

Acquired factor XIII deficiency in myeloid neoplasms: case series and review of literature.

Acquired factor XIII (FXIII) deficiency is a rare disorder that could be associated with autoimmune and malignant disorders with a high risk of bleeding. In acute leukemias, acquired FXIII deficiency has been reported and replacement of FXIII helped to control significant bleeding. Here, we report four cases of myeloid neoplasms to have acquired FXIII deficiency with interesting concomitant RUNX1 mutation in the molecular background of two patients.

Evaluating the Effect of Vitamin D Supplementation on Type 2 Diabetes Risk: A Systematic Review.

Although observational studies have linked vitamin D deficiency to diabetes, it is unknown if taking vitamin D supplements can reduce the chance of developing type 2 diabetes mellitus (T2DM). The purpose of this systematic review is to determine whether vitamin D supplementation lowers the risk of type 2 diabetes. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to search for studies based on pre-established inclusion and exclusion criteria.

Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia.

Chemotherapy-induced cytopenia (CIC) is characterized by neutropenia, anemia, and thrombocytopenia, which are common and serious complications in cancer treatment. These conditions affect approximately 60% of patients undergoing chemotherapy and can significantly impact quality of life, treatment continuity, and overall survival. The use of growth factors, including granulocyte colony-stimulating factors (GCSFs), erythropoietin-stimulating agents (ESAs), and thrombopoietin receptor agonists (TPO-RAs), has emerged as a promising strategy for managing CIC.